Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?
Summary The rapid emergence of COVID-19 has sent shockwaves through healthcare systems globally, with cancer patients at increased risk. The interplay of the virus and host immune system has been implicated in the development of ARDS. Immunotherapy agents have the potential to adversely potentiate t...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2020-09, Vol.123 (5), p.691-693 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 693 |
|---|---|
| container_issue | 5 |
| container_start_page | 691 |
| container_title | British journal of cancer |
| container_volume | 123 |
| creator | Pickles, Oliver J. Lee, Lennard Y. W. Starkey, Thomas Freeman-Mills, Luke Olsson-Brown, Anna Cheng, Vinton Hughes, Daniel J. Lee, Alvin Purshouse, Karin Middleton, Gary |
| description | Summary
The rapid emergence of COVID-19 has sent shockwaves through healthcare systems globally, with cancer patients at increased risk. The interplay of the virus and host immune system has been implicated in the development of ARDS. Immunotherapy agents have the potential to adversely potentiate this phenomenon, requiring careful real-world observation. |
| doi_str_mv | 10.1038/s41416-020-0930-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7296191</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2475029819</sourcerecordid><originalsourceid>FETCH-LOGICAL-c498t-fc58585d0129ed702891adeaeb2bee394dfd39a163ccea22b8bfa6ae4c4475503</originalsourceid><addsrcrecordid>eNp9Uctu2zAQJIoGjZP2A3opCPSshA89yB5aBG4eBgLkkvZKUNTKVmyJ6pJy4b8PA6dpckjAw4I7s7OzGEI-c3bCmVSnIec5LzMmWMa0ZFn1jsx4IUXGlajekxljrEqIYIfkKIS79NVMVR_IoRRFXipZzMjfRd9PA1C3ArcefTdEWm-8W9sGvlGEDdjQDUsaV0BrBLsO1CO1dEQfwcVum9oWsQOk0dP5ze_Fz4xrGmALCNS6KUJSCWOHNnrc0bAbGvQ9_PhIDlq7CfDpsR6TXxfnt_Or7PrmcjE_u85crlXMWleo9BrGhYamYkJpnqxZqEUNIHXetI3UlpfSObBC1KpubWkhd3leFQWTx-T7Xnec6h4aB0NEuzEjdr3FnfG2My-RoVuZpd-aSuiSa54Evj4KoP8zQYjmzk84JM9GpBVMaMX12yypOReiLBOL71kOfQgI7ZMPzsxDomafqEmJmodETZVmvjw_4GniX4SJIPaEkKBhCfh_9euq97TXra4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2439112266</pqid></control><display><type>article</type><title>Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Pickles, Oliver J. ; Lee, Lennard Y. W. ; Starkey, Thomas ; Freeman-Mills, Luke ; Olsson-Brown, Anna ; Cheng, Vinton ; Hughes, Daniel J. ; Lee, Alvin ; Purshouse, Karin ; Middleton, Gary</creator><creatorcontrib>Pickles, Oliver J. ; Lee, Lennard Y. W. ; Starkey, Thomas ; Freeman-Mills, Luke ; Olsson-Brown, Anna ; Cheng, Vinton ; Hughes, Daniel J. ; Lee, Alvin ; Purshouse, Karin ; Middleton, Gary</creatorcontrib><description>Summary
The rapid emergence of COVID-19 has sent shockwaves through healthcare systems globally, with cancer patients at increased risk. The interplay of the virus and host immune system has been implicated in the development of ARDS. Immunotherapy agents have the potential to adversely potentiate this phenomenon, requiring careful real-world observation.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/s41416-020-0930-7</identifier><identifier>PMID: 32546835</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/4028/67 ; 692/4028/67/1059/2325 ; B7-H1 Antigen - antagonists & inhibitors ; Betacoronavirus - immunology ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Clinical Decision-Making ; Comment ; Coronavirus Infections - epidemiology ; Coronavirus Infections - immunology ; Coronavirus Infections - virology ; Coronaviruses ; COVID-19 ; CTLA-4 Antigen - antagonists & inhibitors ; Drug Resistance ; Epidemiology ; Humans ; Immune checkpoint ; Immune system ; Immunosuppression Therapy - adverse effects ; Immunosuppression Therapy - methods ; Immunosuppressive Agents - adverse effects ; Immunosuppressive Agents - pharmacology ; Immunosuppressive Agents - therapeutic use ; Immunotherapy ; Incidence ; Interleukin-6 - antagonists & inhibitors ; Interleukin-6 - blood ; Molecular Medicine ; Neoplasms - therapy ; Oncologists - psychology ; Oncology ; Pandemics ; Pneumonia, Viral - epidemiology ; Pneumonia, Viral - immunology ; Pneumonia, Viral - virology ; Respiratory Distress Syndrome - immunology ; SARS-CoV-2 ; Severe acute respiratory syndrome ; Treatment Outcome</subject><ispartof>British journal of cancer, 2020-09, Vol.123 (5), p.691-693</ispartof><rights>Cancer Research UK 2020</rights><rights>Cancer Research UK 2020.</rights><rights>Cancer Research UK 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c498t-fc58585d0129ed702891adeaeb2bee394dfd39a163ccea22b8bfa6ae4c4475503</citedby><cites>FETCH-LOGICAL-c498t-fc58585d0129ed702891adeaeb2bee394dfd39a163ccea22b8bfa6ae4c4475503</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296191/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296191/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32546835$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pickles, Oliver J.</creatorcontrib><creatorcontrib>Lee, Lennard Y. W.</creatorcontrib><creatorcontrib>Starkey, Thomas</creatorcontrib><creatorcontrib>Freeman-Mills, Luke</creatorcontrib><creatorcontrib>Olsson-Brown, Anna</creatorcontrib><creatorcontrib>Cheng, Vinton</creatorcontrib><creatorcontrib>Hughes, Daniel J.</creatorcontrib><creatorcontrib>Lee, Alvin</creatorcontrib><creatorcontrib>Purshouse, Karin</creatorcontrib><creatorcontrib>Middleton, Gary</creatorcontrib><title>Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Summary
The rapid emergence of COVID-19 has sent shockwaves through healthcare systems globally, with cancer patients at increased risk. The interplay of the virus and host immune system has been implicated in the development of ARDS. Immunotherapy agents have the potential to adversely potentiate this phenomenon, requiring careful real-world observation.</description><subject>692/4028/67</subject><subject>692/4028/67/1059/2325</subject><subject>B7-H1 Antigen - antagonists & inhibitors</subject><subject>Betacoronavirus - immunology</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Clinical Decision-Making</subject><subject>Comment</subject><subject>Coronavirus Infections - epidemiology</subject><subject>Coronavirus Infections - immunology</subject><subject>Coronavirus Infections - virology</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>CTLA-4 Antigen - antagonists & inhibitors</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Humans</subject><subject>Immune checkpoint</subject><subject>Immune system</subject><subject>Immunosuppression Therapy - adverse effects</subject><subject>Immunosuppression Therapy - methods</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Immunotherapy</subject><subject>Incidence</subject><subject>Interleukin-6 - antagonists & inhibitors</subject><subject>Interleukin-6 - blood</subject><subject>Molecular Medicine</subject><subject>Neoplasms - therapy</subject><subject>Oncologists - psychology</subject><subject>Oncology</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - epidemiology</subject><subject>Pneumonia, Viral - immunology</subject><subject>Pneumonia, Viral - virology</subject><subject>Respiratory Distress Syndrome - immunology</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome</subject><subject>Treatment Outcome</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9Uctu2zAQJIoGjZP2A3opCPSshA89yB5aBG4eBgLkkvZKUNTKVmyJ6pJy4b8PA6dpckjAw4I7s7OzGEI-c3bCmVSnIec5LzMmWMa0ZFn1jsx4IUXGlajekxljrEqIYIfkKIS79NVMVR_IoRRFXipZzMjfRd9PA1C3ArcefTdEWm-8W9sGvlGEDdjQDUsaV0BrBLsO1CO1dEQfwcVum9oWsQOk0dP5ze_Fz4xrGmALCNS6KUJSCWOHNnrc0bAbGvQ9_PhIDlq7CfDpsR6TXxfnt_Or7PrmcjE_u85crlXMWleo9BrGhYamYkJpnqxZqEUNIHXetI3UlpfSObBC1KpubWkhd3leFQWTx-T7Xnec6h4aB0NEuzEjdr3FnfG2My-RoVuZpd-aSuiSa54Evj4KoP8zQYjmzk84JM9GpBVMaMX12yypOReiLBOL71kOfQgI7ZMPzsxDomafqEmJmodETZVmvjw_4GniX4SJIPaEkKBhCfh_9euq97TXra4</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Pickles, Oliver J.</creator><creator>Lee, Lennard Y. W.</creator><creator>Starkey, Thomas</creator><creator>Freeman-Mills, Luke</creator><creator>Olsson-Brown, Anna</creator><creator>Cheng, Vinton</creator><creator>Hughes, Daniel J.</creator><creator>Lee, Alvin</creator><creator>Purshouse, Karin</creator><creator>Middleton, Gary</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20200901</creationdate><title>Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?</title><author>Pickles, Oliver J. ; Lee, Lennard Y. W. ; Starkey, Thomas ; Freeman-Mills, Luke ; Olsson-Brown, Anna ; Cheng, Vinton ; Hughes, Daniel J. ; Lee, Alvin ; Purshouse, Karin ; Middleton, Gary</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c498t-fc58585d0129ed702891adeaeb2bee394dfd39a163ccea22b8bfa6ae4c4475503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>692/4028/67</topic><topic>692/4028/67/1059/2325</topic><topic>B7-H1 Antigen - antagonists & inhibitors</topic><topic>Betacoronavirus - immunology</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Clinical Decision-Making</topic><topic>Comment</topic><topic>Coronavirus Infections - epidemiology</topic><topic>Coronavirus Infections - immunology</topic><topic>Coronavirus Infections - virology</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>CTLA-4 Antigen - antagonists & inhibitors</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Humans</topic><topic>Immune checkpoint</topic><topic>Immune system</topic><topic>Immunosuppression Therapy - adverse effects</topic><topic>Immunosuppression Therapy - methods</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Immunotherapy</topic><topic>Incidence</topic><topic>Interleukin-6 - antagonists & inhibitors</topic><topic>Interleukin-6 - blood</topic><topic>Molecular Medicine</topic><topic>Neoplasms - therapy</topic><topic>Oncologists - psychology</topic><topic>Oncology</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - epidemiology</topic><topic>Pneumonia, Viral - immunology</topic><topic>Pneumonia, Viral - virology</topic><topic>Respiratory Distress Syndrome - immunology</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pickles, Oliver J.</creatorcontrib><creatorcontrib>Lee, Lennard Y. W.</creatorcontrib><creatorcontrib>Starkey, Thomas</creatorcontrib><creatorcontrib>Freeman-Mills, Luke</creatorcontrib><creatorcontrib>Olsson-Brown, Anna</creatorcontrib><creatorcontrib>Cheng, Vinton</creatorcontrib><creatorcontrib>Hughes, Daniel J.</creatorcontrib><creatorcontrib>Lee, Alvin</creatorcontrib><creatorcontrib>Purshouse, Karin</creatorcontrib><creatorcontrib>Middleton, Gary</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pickles, Oliver J.</au><au>Lee, Lennard Y. W.</au><au>Starkey, Thomas</au><au>Freeman-Mills, Luke</au><au>Olsson-Brown, Anna</au><au>Cheng, Vinton</au><au>Hughes, Daniel J.</au><au>Lee, Alvin</au><au>Purshouse, Karin</au><au>Middleton, Gary</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2020-09-01</date><risdate>2020</risdate><volume>123</volume><issue>5</issue><spage>691</spage><epage>693</epage><pages>691-693</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><abstract>Summary
The rapid emergence of COVID-19 has sent shockwaves through healthcare systems globally, with cancer patients at increased risk. The interplay of the virus and host immune system has been implicated in the development of ARDS. Immunotherapy agents have the potential to adversely potentiate this phenomenon, requiring careful real-world observation.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32546835</pmid><doi>10.1038/s41416-020-0930-7</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2020-09, Vol.123 (5), p.691-693 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7296191 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | 692/4028/67 692/4028/67/1059/2325 B7-H1 Antigen - antagonists & inhibitors Betacoronavirus - immunology Biomedical and Life Sciences Biomedicine Cancer Research Clinical Decision-Making Comment Coronavirus Infections - epidemiology Coronavirus Infections - immunology Coronavirus Infections - virology Coronaviruses COVID-19 CTLA-4 Antigen - antagonists & inhibitors Drug Resistance Epidemiology Humans Immune checkpoint Immune system Immunosuppression Therapy - adverse effects Immunosuppression Therapy - methods Immunosuppressive Agents - adverse effects Immunosuppressive Agents - pharmacology Immunosuppressive Agents - therapeutic use Immunotherapy Incidence Interleukin-6 - antagonists & inhibitors Interleukin-6 - blood Molecular Medicine Neoplasms - therapy Oncologists - psychology Oncology Pandemics Pneumonia, Viral - epidemiology Pneumonia, Viral - immunology Pneumonia, Viral - virology Respiratory Distress Syndrome - immunology SARS-CoV-2 Severe acute respiratory syndrome Treatment Outcome |
| title | Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T17%3A31%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immune%20checkpoint%20blockade:%20releasing%20the%20breaks%20or%20a%20protective%20barrier%20to%20COVID-19%20severe%20acute%20respiratory%20syndrome?&rft.jtitle=British%20journal%20of%20cancer&rft.au=Pickles,%20Oliver%20J.&rft.date=2020-09-01&rft.volume=123&rft.issue=5&rft.spage=691&rft.epage=693&rft.pages=691-693&rft.issn=0007-0920&rft.eissn=1532-1827&rft_id=info:doi/10.1038/s41416-020-0930-7&rft_dat=%3Cproquest_pubme%3E2475029819%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2439112266&rft_id=info:pmid/32546835&rfr_iscdi=true |